<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04890288</url>
  </required_header>
  <id_info>
    <org_study_id>2020-02609</org_study_id>
    <nct_id>NCT04890288</nct_id>
  </id_info>
  <brief_title>Apneic Intubation Critically Ill Children</brief_title>
  <acronym>Penguin</acronym>
  <official_title>aPneic oxygEnation duriNg emerGent intUbation of crItically Ill childreN: a Multi-center Randomized Controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital Inselspital, Berne</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University Hospital, Geneva</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>State Hospital, St. Gallen</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Zurich</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Luzerner Kantonsspital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Kantonsspital Graubuenden</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Ente Ospedaliero Cantonale, Bellinzona</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University Hospital Inselspital, Berne</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study compares the actual standard of care of intubation in Swiss pediatric intensive&#xD;
      care units vs the use of apneic oxygenation using either high flow or low flow oxygen to&#xD;
      prevent hypoxemia and to prolong apnea time during intubation of critically ill children,&#xD;
      with the final aim to improve airway management safety at PICUs. Primary study objective: To&#xD;
      demonstrate that airway management supported by oxygen supplementation (either HFNC or low&#xD;
      flow oxygen) can prevent significant desaturation (SpO2 &gt; 85%) among patients in pediatric&#xD;
      intensive care units (PICU) and neonatal intensive care units (NICU).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Randomized controlled multicenter trial in Swiss pediatric ICUs with randomization to 3&#xD;
      groups: 1) standard of care with conventional preoxygenation with bag-mask ventilation vs 2)&#xD;
      conventional preoxygenation with bag-mask ventilation and apneic oxygenation with low-flow&#xD;
      Oxygen fraction of inspired oxygen (FiO2) 100% 0.2 L/kg/min vs 3) conventional preoxygenation&#xD;
      with bag-mask ventilation and apneic oxygenation with THRIVE FiO2 100% 2L/kg/min.&#xD;
&#xD;
      Eligible children meeting the inclusions criteria will be prepared for oral intubation&#xD;
      according to the standard operating procedure (SOP) of the respective NICU/PICU. SpO2, heart&#xD;
      rate, invasive or non-invasive blood pressure values shall be recorded continuously (for&#xD;
      invasive continuously and for non-invasive intermittently every 2 minutes and 30 seconds),&#xD;
      once the decision to intubate has been made. The sealed envelope for randomization will then&#xD;
      be opened. All patients must be intubated orally. The induction will be performed according&#xD;
      to the clinical needs of the child. All children will be intubated using the C-MAC&#xD;
      videolaryngoscope with a Miller or Macintosh-blades (Karl Storz, Tuttlingen, Germany) age&#xD;
      adopted.&#xD;
&#xD;
      Before oral intubation preoxygenation is performed for 2 minutes with a facemask usually used&#xD;
      at the study site with an FiO2 of 1.0 and flow rates of 6-10L/min in all groups. After&#xD;
      induction, all patients will be paralyzed with an age appropriate dose of muscle relaxant to&#xD;
      ensure apnoea. The dose of the neuromuscular blocking agent and the depth of the anesthesia&#xD;
      shall be adjusted according to clinical parameters such as absent reactions to jaw thrust and&#xD;
      normocardia. In all groups, after induction, bag-mask ventilation with 100% oxygen and flow&#xD;
      rates of 6-10 Lmin-1 will be continued for about 45-60 seconds until apnea sets in.&#xD;
      Thereafter bag-mask ventilation will be stopped and one of the three study interventions will&#xD;
      be applied according to randomization:&#xD;
&#xD;
      Control group: When apnea sets in, deep laryngoscopy and endotracheal oral intubation are&#xD;
      performed without apneic oxygenation.&#xD;
&#xD;
      Intervention group - high flow: Prior to the introduction of the laryngoscope, apneic&#xD;
      oxygenation is commenced with a high-flow nasal cannula flow rate of 2L/kg/min using OptiFlow&#xD;
      system at an FiO2 of 1.0. After starting THRIVE laryngoscopy and tracheal oral intubation is&#xD;
      performed.&#xD;
&#xD;
      Intervention group - low flow: Prior to the introduction of the laryngoscope, the&#xD;
      administration of low-flow oxygen (0.2 l/kg/min) will take place via conventional neonatal&#xD;
      nasal cannula (Intersurgical, Wokingham, Berkshire, United Kingdom). After starting low-flow&#xD;
      oxygen laryngoscopy and tracheal oral intubation is performed.&#xD;
&#xD;
      A chest x-ray, which is a routine procedure, shall be performed at the conclusion of the&#xD;
      procedure to verify the endotracheal tube (ETT) position and rule out a pneumothorax.&#xD;
&#xD;
      Study termination criteria constitute successful intubation or the occurrence of a &quot;Can't&#xD;
      Intubate, Can't Oxygenate&quot; emergency. A maximum of 4 intubation attempts in total may be&#xD;
      performed. The last intubation attempt must be performed by the most experienced physician in&#xD;
      the room. Additional devices like stylet, bougie, etc, can be used at any stage of the&#xD;
      intubation process. If the intubation remains unsuccessful the difficult airway algorithm&#xD;
      will be followed and a supraglottic airway device (SAD) device will be inserted. Unsuccessful&#xD;
      intubation requiring a SAD will lead to immediate study termination. Equipment malfunction&#xD;
      (e.g. HFNC, C-MAC VL) will lead to study cessation. In the event of an unexpected difficult&#xD;
      intubation, the difficult airway algorithm will be followed.&#xD;
&#xD;
      Intervention group - High flow: High-flow nasal cannula oxygen 2L/kg/min using OptiFlow&#xD;
      system by Fisher&amp;Paykel and an oxygen inspiration concentration FiO2 of 1.0; enabling apneic&#xD;
      oxygenation during laryngoscopy.&#xD;
&#xD;
      Picture showing nasal prongs for high-flow oxygen. Intervention group - Low flow: Low-flow&#xD;
      oxygen (100%, 0.2 l/kg/min) via conventional neonatal nasal cannula (Intersurgical,&#xD;
      Wokingham, Berkshire, United Kingdom) enabling apneic oxygenation during laryngoscopy.&#xD;
&#xD;
      Conventionally practiced standard of care with preoxygenation with facemask with an FiO2 of&#xD;
      1.0, followed by bag mask ventilation after induction before oral intubation without apneic&#xD;
      oxygenation.&#xD;
&#xD;
      The investigators will include 210 patients, 70 per group. Assuming a desaturation rate of&#xD;
      40% in the control group and a desaturation rate of max 15% with low-flow oxygen and HFNC,&#xD;
      aiming at a power of 80% and setting an alpha-level at 0.025 the investigators would need&#xD;
      n=56 patients per group. Accounting for some drop-outs, they seek to enroll n=70 patients per&#xD;
      group, i.e. a total of n=210 patients.&#xD;
&#xD;
      In pilot studies to this protocol and in recent published data a maximum desaturation of 10%&#xD;
      was observed during intubation for both therapies.&#xD;
&#xD;
      The difference in desaturation rate between the 2 intervention groups will be analyzed for&#xD;
      non-inferiority.&#xD;
&#xD;
      Assuming a desaturation rate of 85% with HFNC and desaturation rate of 85 % with low-flow&#xD;
      oxygen, aiming at a power of 80% and setting an alpha-level at 0.025 (one-sided&#xD;
      non-inferiority trial), with a non-inferiority limit of 17% the investigators would need n=70&#xD;
      patients per group.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">June 1, 2021</start_date>
  <completion_date type="Anticipated">December 31, 2023</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of patients with desaturation &lt; 85 percent during intubation</measure>
    <time_frame>15 minutes</time_frame>
    <description>To demonstrate that airway management supported by oxygen supplementation (either HFNC or low flow oxygen) can prevent significant desaturation (SpO2 &gt; 85%) among patients in pediatric intensive care units (PICU) and neonatal intensive care units (NICU).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of patients with desaturation low-flow oxygen vs. HFNC</measure>
    <time_frame>15 minutes</time_frame>
    <description>Difference in desaturation between low-flow oxygen and HFNC</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>First attempt success rate</measure>
    <time_frame>15 minutes</time_frame>
    <description>Rate of successful tube placement upon first attempt</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of attempts</measure>
    <time_frame>15 minutes</time_frame>
    <description>overall number of intubation attempts</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time required for intubation</measure>
    <time_frame>5 minutes</time_frame>
    <description>Time required for intubation (in seconds), defined by the moment the laryngoscope passes the lips until successful lung ventilation is confirmed (defined as positive capnography)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of desaturation &lt; 85 percent</measure>
    <time_frame>15 minutes</time_frame>
    <description>Duration of desaturation below 85%</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Level of desaturation &lt; 85 percent</measure>
    <time_frame>15 minutes</time_frame>
    <description>Degree of desaturation below 85%</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">210</enrollment>
  <condition>Airway Management</condition>
  <arm_group>
    <arm_group_label>Intervention group - High flow</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>High-flow nasal cannula oxygen 2L/kg/min using OptiFlow system by Fisher&amp;Paykel and an oxygen inspiration concentration FiO2 of 1.0; enabling apneic oxygenation during laryngoscopy.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Intervention group - Low flow:</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Low-flow oxygen (100%, 0.2 l/kg/min) via conventional neonatal nasal cannula (Intersurgical, Wokingham, Berkshire, United Kingdom) enabling apneic oxygenation during laryngoscopy.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Conventional</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Conventionally practiced standard of care with preoxygenation with facemask with an FiO2 of 1.0, followed by bag mask ventilation after induction before oral intubation without apneic oxygenation.</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Interventional randomized controled trial (RCT) comparing two oxygenation methods to reduce desaturation during intubation vs standard of care.</intervention_name>
    <description>Demonstrate that airway management supported by oxygen supplementation (either HFNC or low flow oxygen) can prevent significant desaturation (SpO2 &gt; 85%) among patients in pediatric intensive care units (PICU) and neonatal intensive care units (NICU).</description>
    <arm_group_label>Intervention group - High flow</arm_group_label>
    <arm_group_label>Intervention group - Low flow:</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Pediatric patients requiring intubation in the pediatric intensive care unit&#xD;
&#xD;
          -  Aged from 37 weeks corrected gestational age to 6 years&#xD;
&#xD;
          -  Legal guardians providing written informed consent before the intervention or delayed&#xD;
             consent in the event that emergency intubation is required&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients with known or suspected difficult/airways&#xD;
&#xD;
          -  Congenital heart disease mandating FiO2 &lt; 1.0, warranting inhalational induction,&#xD;
             requiring ongoing CPR or advanced life support due to respiratory arrest&#xD;
&#xD;
          -  Preterm age &lt; 37 0/7 weeks&#xD;
&#xD;
          -  Patients who cannot be intubated orally&#xD;
&#xD;
          -  Respiratory insufficiency with an SpO2 saturation &lt; 90 % after 2 min of preoxygenation&#xD;
             with FiO2 = 1.0&#xD;
&#xD;
          -  Newborns requiring surfactant within the first 3 days of life&#xD;
&#xD;
          -  Document stating intent to reject participation in research projects or refusal of&#xD;
             intubation or refusal of resuscitation measures&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>37 Weeks</minimum_age>
    <maximum_age>6 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Thomas Riva, MD</last_name>
    <role>Study Chair</role>
    <affiliation>University of Berne</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Francis F Ulmer, MD</last_name>
    <phone>+41316325265</phone>
    <email>francis.ulmer@insel.ch</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Thomas Riva, MD</last_name>
    <phone>+41316321709</phone>
    <email>thomas.riva@insel.ch</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>EOC</name>
      <address>
        <city>Bellinzona</city>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Inselspital</name>
      <address>
        <city>Bern</city>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kantonsspital</name>
      <address>
        <city>Chur</city>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>HUG</name>
      <address>
        <city>Geneva</city>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kantonsspital Luzern</name>
      <address>
        <city>Luzern</city>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kinderspital</name>
      <address>
        <city>Saint Gallen</city>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kinderspital</name>
      <address>
        <city>ZÃ¼rich</city>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Switzerland</country>
  </location_countries>
  <verification_date>May 2021</verification_date>
  <study_first_submitted>December 3, 2020</study_first_submitted>
  <study_first_submitted_qc>May 14, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">May 18, 2021</study_first_posted>
  <last_update_submitted>May 31, 2021</last_update_submitted>
  <last_update_submitted_qc>May 31, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">June 3, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Pediatric</keyword>
  <keyword>Intubation</keyword>
  <keyword>Apnea</keyword>
  <keyword>Desaturation</keyword>
  <keyword>High flow</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Critical Illness</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

